Literature DB >> 26966002

Atrial electrograms improve the accuracy of tachycardia interpretation from ICD and pacemaker recordings: The RATE Registry.

Michael V Orlov1, Haley Q Houde-Walter2, Fujian Qu3, Steven Swiryn4, Albert L Waldo5, David G Benditt6, Brian Olshansky7.   

Abstract

BACKGROUND: Tachycardia diagnoses from implantable device recordings ultimately depend on the analysis of captured electrograms (EGMs). The degree to which atrial EGMs improve tachycardia discrimination, dependent on the level of expertise of the medical professional involved, remains uncertain.
OBJECTIVE: The purpose of this article was to determine whether atrial EGM recordings improve tachycardia discrimination and whether this improvement, if any, varies for professionals with different levels of training.
METHODS: Expert-adjudicated supraventricular tachycardia (SVT) and ventricular tachycardia (VT) dual-chamber EGMs (DEGMs) from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes in the Cardiac Rhythm Management Device Population were provided to electrophysiology specialists, electrophysiology fellows (EPF), and nurse practitioners or physician assistants (NPPA). Each participant diagnosed 112 EGM episodes presented in random sequence (61 VTs and 51 SVTs) and independently categorized each as "SVT," "VT," or "uncertain" in 2 stages. First, participants analyzed ventricular EGMs (VEGMs) alone (atrial channel covered). Second, the tracings were randomized and reanalyzed with atrial EGMs exposed. The diagnostic accuracy of VEGMs alone vs DEGMs was assessed for each group.
RESULTS: For all 3 groups, diagnostic accuracy improved significantly (>20% for VTs and >15% for SVTs; P < .01 for all) when DEGMs were provided. Electrophysiology specialists diagnosed VTs more accurately than did EPF and NPPA (VEGM: 73.1%±7.6% vs 58.7%±15.5% and 56.1%±14.1%; P < .01; DEGM: 98.0%±2.7% vs 90.8%±16.0% and 80.3%±7.4%; P < .01). EPF diagnosed VTs more accurately than did NPPA only when DEGMs were provided. There was no significant intergroup difference in SVT diagnoses.
CONCLUSION: DEGMs are superior to VEGMs alone for tachycardia discrimination at all levels of expertise. The level of training affects diagnostic accuracy with and without atrial EGMs.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Implantable defibrillator; RATE Registry; Supraventricular; Tachycardia; Ventricular

Mesh:

Year:  2016        PMID: 26966002     DOI: 10.1016/j.hrthm.2016.03.013

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  4 in total

1.  The Dx-AF study: a prospective, multicenter, randomized controlled trial comparing VDD-ICD to VVI-ICD in detecting sub-clinical atrial fibrillation in defibrillator patients.

Authors:  Mohammed Shurrab; Amir Janmohamed; Jean-François Sarrazin; Felix Ayala-Paredes; Marcio Sturmer; Randall Williams; Satish Toal; Chris Lane; Kevin E Thorpe; Jeff S Healey; Eugene Crystal
Journal:  J Interv Card Electrophysiol       Date:  2017-07-27       Impact factor: 1.900

Review 2.  Atrial high-rate episodes and stroke prevention.

Authors:  A John Camm; Emmanuel Simantirakis; Andreas Goette; Gregory Y H Lip; Panos Vardas; Melanie Calvert; Gregory Chlouverakis; Hans-Christoph Diener; Paulus Kirchhof
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

3.  Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial.

Authors:  George Thomas; Daniel Y Choi; Harish Doppalapudi; Mark Richards; Sei Iwai; Emile G Daoud; Mahmoud Houmsse; Arvindh N Kanagasundram; Sumeet K Mainigi; Steven A Lubitz; Jim W Cheung
Journal:  J Cardiovasc Electrophysiol       Date:  2019-08-05

Review 4.  Are atrial high rate episodes (AHREs) a precursor to atrial fibrillation?

Authors:  Ahsan A Khan; Giuseppe Boriani; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2019-09-14       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.